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A Co-CRISPR Strategy for Efﬁcient Genome Editing
in Caenorhabditis elegans
Heesun Kim,*,†,1 Takao Ishidate,†,‡,1 Krishna S. Ghanta,*,† Meetu Seth,*,†,‡ Darryl Conte Jr.,*,†
Masaki Shirayama,*,†,‡,2 and Craig C. Mello*,†,‡,2
*Program in Molecular Medicine, †RNA Therapeutics Institute, and ‡Howard Hughes Medical Institute, University of Massachusetts
Medical School, Worcester, Massachusetts 01605
ABSTRACT Genome editing based on CRISPR (clustered regularly interspaced short palindromic repeats)-associated nuclease (Cas9)
has been successfully applied in dozens of diverse plant and animal species, including the nematode Caenorhabditis elegans. The rapid
life cycle and easy access to the ovary by micro-injection make C. elegans an ideal organism both for applying CRISPR-Cas9 genome
editing technology and for optimizing genome-editing protocols. Here we report efﬁcient and straightforward CRISPR-Cas9 genome-
editing methods for C. elegans, including a Co-CRISPR strategy that facilitates detection of genome-editing events. We describe
methods for detecting homologous recombination (HR) events, including direct screening methods as well as new selection/counter-
selection strategies. Our ﬁndings reveal a surprisingly high frequency of HR-mediated gene conversion, making it possible to rapidly
and precisely edit the C. elegans genome both with and without the use of co-inserted marker genes.
SEQUENCE-speciﬁc immunity mechanisms such as RNAinterference (Voinnet 2001; Zamore 2001; Grishok and
Mello 2002; Hannon 2002) and CRISPR (clustered regularly
interspaced short palindromic repeats)-Cas9 (Horvath and
Barrangou 2010; Bhaya et al. 2011; Terns and Terns 2011;
Wiedenheft et al. 2012) provide sophisticated cellular de-
fense against invasive nucleic acids. Understanding how
these defense systems work has enabled researchers to re-
direct them at cellular targets, providing powerful tools for
manipulating both gene expression and the cellular genome
itself. The CRISPR-Cas9 system is a bacterial antiviral mech-
anism that captures fragments of viral DNA in specialized
genomic regions for reexpression as small-guide RNAs
(sgRNAs) (Bhaya et al. 2011; Terns and Terns 2011; Wiedenheft
et al. 2012). In bacterial cells Cas9–sgRNA complexes provide
acquired immunity against viral pathogens (Bhaya et al.
2011; Terns and Terns 2011; Wiedenheft et al. 2012). When
coexpressed along with an artiﬁcial sgRNA designed to target
a cellular gene, the Cas9 nuclease has been shown to efﬁ-
ciently direct the formation of double-strand breaks at the
corresponding target locus (Jinek et al. 2012). Though bac-
terial in origin, this mechanism works efﬁciently even within
the context of eukaryotic chromatin (Gilbert et al. 2013).
Genome editing using CRISPR-Cas9 has recently been dem-
onstrated in numerous organisms, providing a powerful new
tool with rapidly growing—if not inﬁnite—potential for diverse
biological applications (Bassett et al. 2013; Chang et al. 2013;
Cho et al. 2013a; Cong et al. 2013; Dicarlo et al. 2013; Dickinson
et al. 2013; Feng et al. 2013, 2014; Friedland et al. 2013; Gratz
et al. 2013; Jiang et al. 2013; Mali et al. 2013b; Wang et al.
2013; Ma et al. 2014; Yu et al. 2014; Zhou et al. 2014).
The CRISPR-Cas9 system has also been successfully
applied to Caenorhabditis elegans. Methods that have been
used to express Cas9 include mRNA injection and transgene-
driven expression from a constitutive or an inducible pro-
moter (Chen et al. 2013; Chiu et al. 2013; Cho et al. 2013b;
Dickinson et al. 2013; Friedland et al. 2013; Katic and Grosshans
2013; Lo et al. 2013; Tzur et al. 2013; Waaijers et al. 2013;
Zhao et al. 2014). The U6 promoter has been used to drive
sgRNA expression (Chiu et al. 2013; Dickinson et al. 2013;
Friedland et al. 2013; Katic and Grosshans 2013; Waaijers
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et al. 2013). The system has been used widely to produce
small insertions and deletions (indels) that shift the reading
frame of the target gene, often resulting in premature termi-
nation of translation and loss-of-function phenotypes (Chiu
et al. 2013; Cho et al. 2013b; Friedland et al. 2013; Lo et al.
2013; Waaijers et al. 2013). In addition, single-strand oligo-
nucleotides have been used as donor molecules to precisely
alter a target gene through homologous recombination (HR)
(Zhao et al. 2014), and a selection scheme has been devel-
oped that allows the HR-mediated insertion of large sequence
tags such as GFP (Chen et al. 2013; Dickinson et al. 2013;
Tzur et al. 2013).
Despite these important advances, current CRISPR pro-
tocols for inducing indels and HR events in C. elegans could
beneﬁt from reﬁnement. For example, different sgRNAs tar-
geting the same gene can result in substantially variable
DNA cleavage efﬁciencies (Bassett et al. 2013; Chen et al.
2013; Wang et al. 2014); thus, identifying active sgRNAs
can be time consuming and costly.
In this study, we investigate several strategies with which
to streamline CRISPR-Cas9-mediated genome editing in
C. elegans. We describe a Co-CRISPR strategy that can facil-
itate the identiﬁcation of functional sgRNAs and can enrich
for transgenic animals carrying an HR event. We show that
HR events can be identiﬁed without the need for selection at
a rate of 1% to as high as 10% of F1 transgenic animals
scored. This high frequency allows HR events to be identiﬁed
by directly scoring for GFP expression or by PCR screening to
detect HR-induced DNA polymorphisms. Direct screening
allows precise genome alterations that minimize the footprint
of DNA alterations, such as inserted selectable markers, at the
target locus. However in some cases, such as whole-gene de-
letion assays that may induce lethality, selection can be useful
for both identifying and maintaining HR events. We therefore
describe a straightforward selection/counterselection pro-
tocol that facilitates recovery of HR events where having
a marker inserted at the target site might be tolerated or
useful. Together the ﬁndings presented here take much of the
guesswork out of using the CRISPR-Cas9 system in C. elegans,
and the Co-CRISPR strategy employed here may also prove
useful in other organisms.
Materials and Methods
Genetics
All strains in this study were derived in the Bristol N2 back-
ground and maintained on nematode growth medium
(NGM) plates seeded with OP50 (Brenner 1974).
Selection of sgRNA target sequences
We manually searched for target sequences consisting of
G(N)19NGG (Wiedenheft et al. 2012; Friedland et al. 2013)
near the desired mutation site. For HR-mediated repair
experiments such as gfp knock-in and introduction of point
mutation, we selected the target sequences where it was pos-
sible to introduce a silent mutation in the PAM site. Target
sequences are listed in Supporting Information, Table S1.
Preparation of sgRNA constructs
We replaced the unc-119 target sequence in pU6::unc-119
sgRNA vector (Friedland et al. 2013) with the desired target
sequence using overlap extension PCR. The pU6::unc-119
sgRNA vector was diluted to 2 ng/ml and used as a template
to generate two overlapping fragments. The ﬁrst was ampli-
ﬁed using the primers CMo16428 and sgRNA R, resulting
in the U6 promoter fused to the GN19 target sequence
(U6p::GN19). The second was ampliﬁed using the primers
CMo16429 and sgRNA F, resulting in the GN19 target se-
quence fused to the sgRNA scaffold and U6 39-UTR. These
two PCR products were mixed together, diluted 1:50, and
used as a template for a PCR reaction with primers CMo16428
and CMo16429. The resulting pU6::target sequence::sgRNA
scaffold::U6 39-UTR fusion products were gel puriﬁed and
inserted into the pCR-Blunt II-TOPO vector (Invitrogen, no.
K2800-20). We used iProof high-ﬁdelity DNA polymerase
(Bio-Rad, no. 172-5300) in all PCR reactions above to mini-
mize errors of PCR ampliﬁcation, and all the constructs were
conﬁrmed by DNA sequencing. Primers sequences are listed in
Table S2.
Preparation of HR donor vectors
pie-1 donor plasmids (point mutations and gfp and ﬂag
fusions): pie-1 genomic sequence (LGIII:12,425,767-12,428,049)
was ampliﬁed using the primers C_PIE-1 PF and C-PIE-1 PR
and the resulting PCR product was inserted into the pCR-
Blunt II-TOPO vector (Invitrogen, no. K2800-20).
The K68A and K68R mutations were introduced by PCR
sewing (or overlap extension PCR). The pie-1 plasmid de-
scribed above was used as a template to generate overlap-
ping PCR products with the corresponding site-speciﬁc
mutations. The overlapping PCR products were mixed to-
gether (1:1), diluted 50-fold with water, and used as a tem-
plate in the PCR-sewing step with an external primer pair.
The fused PCR products were gel puriﬁed and cloned into
the pCR-Blunt II-TOPO vector.
For building gfp::pie-1 donor constructs, an NheI restric-
tion site was inserted immediately after and in frame with
the start codon of pie-1 by PCR sewing. A plasmid containing
wild-type or mutant pie-1 sequence was used as a template
to generate a left-arm PCR product ﬂanked by BsiWI and
NheI restriction sites and a right-arm PCR product ﬂanked
by NheI and NgoMIV restriction sites. The products were
digested with NheI, puriﬁed using a PCR cleanup kit, and
ligated together. The ligated products were cloned into the
pCR-Blunt II-TOPO vector, and plasmids containing the ap-
propriately ligated fragments were identiﬁed. A BsiWI and
NgoMIV fragment, containing the in frame NheI site imme-
diately after the start codon, was released and ligated to
similarly digested pie-1 constructs. The GFP coding region
ampliﬁed from pPD95.75 (Addgene) was inserted into the
NheI site.
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For pie-1::gfp or pie-1::ﬂag, a 1.6-kb fragment (LGIII
12,428,172–12,429,798) was ampliﬁed from genomic DNA
and inserted into the pCR-Blunt II-TOPO vector (Invitrogen,
no. K2800-20). Overlap extension PCR was used to introduce
an NheI site immediately before the stop codon in this frag-
ment of pie-1. A 33ﬂag sequence (gattacaaagaccatgatggt
gactataaggatcatgatattgactataaagacgatgacgataag) was inserted
into the NheI site.
Finally, we used PCR sewing to introduce silent muta-
tions that disrupt the PAM site (NGG to NTG) in each HR
donor. The above plasmids were used as templates to generate
the initial PCR products for PCR sewing. The ﬁnal products
were cloned into the pCR-Blunt II-TOPO vector.
We used iProof high-ﬁdelity DNA polymerase (Bio-Rad,
no. 172-5300) in all PCR reactions above. Primers are listed
in Table S3.
mCherry::vet-2 and ﬂag::vet-2 donor construct: A 2411-
bp DNA fragment of the vet-2 gene, including 1249 bp of
sequence upstream and 1162 bp downstream of the vet-2
start codon (corresponding to the genomic sequence
LGI:10,845,543-10,847,953), was ampliﬁed from genomic
DNA and inserted into pBluescript KS (+) vector (Addgene).
An XmaI site was introduced by PCR immediately after the
vet-2 start codon. The mcherry coding sequence ampliﬁed
from pCFJ90 (Addgene) or 33ﬂag sequence was inserted
into the XmaI site.
smo-1::ﬂag donor plasmid: smo-1 genomic sequence (LGI:
1,340,243–1,341,558) was ampliﬁed from N2 genomic DNA
and inserted into the pCR-Blunt II-TOPO vector (Invitrogen,
no. K2800-20). Overlap extension PCR was used to intro-
duce an NheI site immediately before the stop codon in this
fragment of smo-1. The resulting PCR product was cloned
into the pCR-Blunt II-TOPO vector. A 33ﬂag fragment with
NheI overhangs was generated by annealing two overlap-
ping oligonucleotides and ligated into the smo-1 donor plas-
mid. We mutated the PAM site (Figure S3C) as described for
the pie-1 donors above.
gfp::pie-1 for MosSCI: A 3744-bp fragment (ScaI–NotI) con-
taining the pie-1 promoter was excised from pID3.01B
(Addgene) and inserted into a modiﬁed MosSCI LGII vector
(B1496) in which a NotI site was added to pCFJ151 (Frokjaer-
Jensen et al. 2008; Shirayama et al. 2012). A 2631-bp PCR
fragment containing the pie-1 open reading frame (ORF) and
39-UTR was then inserted into the resulting plasmid to make
a gfp::pie-1 plasmid for MosSCI. The plasmid was injected into
the strain EG4322 at a concentration of 10 ng/ml by direct
injection method to insert a single-copy gfp::pie-1 transgene
on chromosome II at position 8,420,159.
BSD-fusion to pie-1: The nucleotide sequence of the
Blasticidin S resistance gene (BSD) from Aspergillus terreus
was codon optimized for C. elegans and an artiﬁcial intron
(gtaagagattttttaaaaatttattttttacactgttttttctcag) was inserted
into the middle of the BSD ORF: the entire gene was de novo
synthesized by GenScript. The BSD fragment containing the
BSD ORF (439 bp), rpl-28 promoter (568 bp), and rpl-28 39-
UTR (568 bp) was inserted into pBluescript KS (+) vector
(Addgene). The complete sequence of BSD marker is avail-
able upon request. A 1077-bp fragment of pie-1 left homol-
ogy was inserted into the XbaI site before the rpl-28
promoter and a 1017-bp fragment of pie-1 right homology
was inserted into the SalI–ApaI site after the rpl-28 39-UTR.
Blasticidin S (AG scientiﬁc, no. B-1247) was used to select
animals transformed with the BSD gene.
cb-unc-119(+) donor plasmid: Cbr-unc-119(+) (2216 bp)
was ampliﬁed from pCFJ151 (Frokjaer-Jensen et al. 2008;
Shirayama et al. 2012) using primers tailed on the 59 end
and the 39 end with the loxP (ataacttcgtataatgtatgctatac
gaagttat) sequence (Dickinson et al. 2013). This loxP::
Cbr-unc-119(+)::loxP fragment was inserted into pBluescript-
KS(+) vector (Addgene) linearized with XhoI. A 1006-bp
fragment of the sequence upstream of the oma-1(tm1396)
deletion (LGIV: 8,884,663-8,891,662) was inserted into
the SpeI site on one side of the loxP::Cbr-unc-119(+)::loxP
cassette, and a 1000-bp fragment of the sequence down-
stream of the oma-1(tm1396) deletion (LGIV:8,887,927-
8,894,926) was inserted into the ApaI site after the loxP
site.
Preparation of heat-shock-Cas9 plasmid
The Mos1 transposase ORF in pJL44 (Addgene) was replaced
with Cas9 from Peft3::Cas9 vector (Friedland et al. 2013) to
generate hs::Cas9 (pWU34) construct.
Micro-injection
DNA mixtures were micro-injected into the gonads of young
adult worms. Plasmids for injection were prepared using
a midiprep plasmid puriﬁcation kit (Qiagen, no. 12143). For
Co-CRISPR, we injected 50 ng/ml each vectors [Cas9 vector,
unc-22 sgRNA vector (Co-CRISPR), two untested-sgRNAs,
and pRF4::rol-6(su1006)] (Figure 2A). Micro-injection mix-
tures for HR contained 50 ng/ml each Cas9 vector, sgRNA
vector, pRF4::rol-6(su1006), and HR donor vector. The ﬁnal
concentration of DNA in the injection mix did not exceed
200 ng/ml. For injection mixes with ﬁve different plasmids,
40 ng/ml of each plasmid was added. For HR experiments,
we injected 40–60 worms and for disruptions, 20–30 worms.
After recovering from injection, each worm was placed onto
an individual plate.
Screening for indels using Co-CRISPR
To validate untested sgRNAs we injected mixtures con-
taining the unc-22 sgRNA and up to several untested
sgRNAs (as described above). Three days after injection,
F1 rollers and F1 twitchers were picked individually to
plates and allowed to produce F2 progeny for 2–3 days.
F1 twitchers and F1 rollers with twitching F2 progeny
were then transferred to 20 ml lysis buffer for PCR, PAGE
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(see below), and/or DNA sequencing analysis. Total time
from injection to indel detection was 6–7 days.
Screening for HR events
Direct detection of GFP: This procedure works for donor
vectors that cannot drive GFP without ﬁrst integrating into
the genomic target site. For GFP::PIE-1 it was necessary to
mount gravid F1 rollers three at a time under coverslips on
2% agarose pads for screening at 403 magniﬁcation using
a Zeiss Axioplan2 microscope. For bright GFP constructs, it
should be possible to screen using a ﬂuorescence dissecting
scope. GFP-positive animals were recovered by carefully re-
moving the coverslip and transferring to individual plates.
After laying eggs for 1 day they were individually lysed in 20
ml lysis buffer for PCR conﬁrmation of the GFP insertion.
GFP-positive F2 homozygotes were then identiﬁed and correct
insertion of GFP was conﬁrmed by DNA sequencing. Total time
from injection to recovery of heterozygotes was 3–4 days.
PCR detection: F1 rollers were picked individually to plates
and allowed to lay eggs for 1 day. For the Co-CRISPR assay,
F1 rollers were allowed to produce F2 progeny for 2–3 days so
that F2 twitcher progeny could be identiﬁed. (Note that F1
roller animals that segregate twitching progeny should be se-
lected as these animals exhibit the highest HR frequency, while
nonrolling F1 twitchers should be avoided; see Results and
Discussion). F1 animals were then transferred into lysis buffer
in indexed PCR tubes and were screened using primers outside
the homology arms followed by restriction enzyme digestion to
detect the insertion. In some experiments, 1 ml of the initial
PCR reaction was used as a template for a second PCR reaction
with primers within the donor sequences. Although useful, this
latter procedure gave several false positives in our hands. Total
time from injection to recovery of heterozygotes was 4 days.
For the Co-CRISPR strategy, 3 more days were required to
recover heterozygotes.
Selection/counterselection method: Four days after injec-
tion, gravid F1 rolling adults were placed in groups of 10–15
animals per plate onto media containing ivermectin and blas-
ticidin (Figure 4B). After 3–4more days, the plates were scored
for viable, fertile progeny. Insertion of BSD at the target locus
was then conﬁrmed by PCR and DNA sequencing (as described
above). The total time from injection to recovery of HR events
was 7–10 days. Although slightly longer in duration this pro-
cedure required 10 times less labor as only the relatively rare
viable populations were subject to PCR and DNA sequence
analysis. For donor molecules containing the Cbr-unc-119(+)
selection, the procedure was essentially the same; however,
blasticidin was omitted from the selective media and the re-
cipient strain was both Cbr-unc-119 mutant and ivermectin re-
sistant. Primers for screening HR events are listed in Table S3.
Imaging
Images were captured with an ORCA-ER digital camera
(Hamamatsu) and AxioVision (Zeiss) software.
Screening for small indels by PCR and PAGE
We designed primers to amplify (30 cycles) PCR products
of 60–65 bp encompassing the CRISPR-Cas9 target site. PCR
products were resolved on 15% polyacrylamide gels to dis-
tinguish dsDNA molecules that differ by as little as 1 bp. We
found that we could screen for indels even in HR experi-
ments, but it required two PCR steps. In the ﬁrst PCR re-
action (20 cycles), primers outside of the homology arms
were used to avoid amplifying the donor sequence. In the
second reaction (15 cycles), 1 ml of the ﬁrst PCR reaction
was used as a template to generate the 60- to 65-bp PCR
product encompassing the CRISPR-Cas9 target site. TaKaRa
Ex Taq (Takara, no. RR001) was used for the PCR reactions
above. Primer sequences are listed in Table S3.
Immunoblotting
One hundred adult worms were lysed in 80 ml of 13 sample
buffer (25 ml of M9 containing 100 worms, 25 ml of 23 lysis
buffer, 20 ml of 43 NuPAGE LDS Sample buffer (Invitrogen,
no. NP0008), and 10 ml of b-mercaptoethanol by boiling for
20 min, freezing, and boiling again for 10 min. The worm
lysate proteins were separated on 4–12% NuPAGE Tris–
acetate Mini Gels (Invitrogen, no. NP0335BOX). Proteins
were transferred to Immun-Blot PVDF Membrane (Bio-
Rad, no.162-0177) at 100 V for 1 hr at 4. Mouse mono-
clonal anti-PIE-1 antibody (P4G5) (Mello et al. 1996) and
rabbit polyclonal anti-PGL-1 antibody was used at 1:50 and
1:500, respectively.
Results and Discussion
Using a visible cotransformation marker enriches for
genome-editing events
While conducting CRISPR-Cas9 experiments to induce
mutations in the pie-1 gene, we used the dominant co-
injection marker rol-6 to monitor injection quality. From
60 injected animals, we obtained 93 fertile F1 rollers. Re-
markably, we noted that several of these F1 rollers (5/93)
produced 100% dead embryos exhibiting the distinctive
pie-1 maternal-effect embryonic lethal phenotype (Mello
et al. 1996) (Figure 1A). Genomic sequencing of these F1
adults identiﬁed lesions in the pie-1 gene consistent with
Cas9-directed cleavage (Figure 1B). In some cases the ma-
ternal and paternal alleles exhibited distinct lesions, while in
others, the same lesion was found in both alleles (Figure
1B). Since the DNA was delivered into the ovary of an adult,
after the switch from sperm to oocyte development, the
paternal allele must have been targeted in the F1 zygote
soon after fertilization. The fact that both alleles exhibit
identical lesions in some animals suggests that a chromosome
previously cut by Cas9 and repaired by non-homologous end
joining (NHEJ) was used as a donor molecule to copy the
lesion into the homolog.
If the activation of Cas9 in the germline is broadly or
nonspeciﬁcally mutagenic, then some injected animals would
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be expected to segregate novel mutants, including mutants
with non-pie-1 dead-embryo phenotypes. To look for evi-
dence of off-target mutagenesis, we screened among the
progeny of F1 rollers for animals producing dead embryos,
or other visible phenotypes. A careful examination of F2 and
F3 populations revealed 17 populations from 93 F1 rollers
that segregated numerous dead embryos (Figure 1A). How-
ever, examination of these dead embryos by Nomarski mi-
croscopy revealed the distinctive pie-1 mutant phenotype
and no other phenotypes. Each of these 17 strains segregated
pie-1 homozygotes at the expected Mendelian frequency,
indicating that the original F1 rollers were heterozygous
for pie-1 loss-of-function mutations. Sequencing of these
strains revealed indels in the region of the pie-1 gene tar-
geted by CRISPR-Cas9 (Figure 1B). In some cases, to avoid
the delay and added cost of DNA sequencing, genomic DNA
prepared from lysates of each candidate was ampliﬁed as
60-bp PCR products that were then analyzed on a 15%
PAGE gel. This analysis easily detected lesions as small as
5 nt (Figure 1B and Figure S1A).
In addition to F1 rollers, we randomly selected F1 nonroller
sibling progeny that were produced during the same time
window as the F1 rollers. Among 100 nonroller siblings, we
failed to ﬁnd animals segregating dead embryos. Thus, using
the dominant visible rol-6 marker to identify F1 transgenic
animals (rollers) also identiﬁed animals in which Cas9 was
active. It is important to note, however, that very few of the
animals with pie-1 mutations continued to exhibit the roller
phenotype in subsequent generations, suggesting that the
rol-6 transgene expression was transient and present only
in the F1 generation.
A Co-CRISPR strategy to detect genome-editing events
In practice, we have found that about half of sgRNAs tested
are not effective. Thus, while the rol-6 marker was clearly
useful for ﬁnding animals with CRISPR-Cas9-induced lesions,
we nevertheless frequently had to screen through dozens or
even hundreds of F1 rollers by PCR or sequencing only to
conclude that CRISPR-Cas9 was not active in the injection.
We therefore reasoned that co-injecting a proven sgRNA
(one that works well and results in an easily recognized
visible phenotype) would allow us to more directly iden-
tify animals in which Cas9 is active. We tested this strategy
using an sgRNA targeting the muscle structural gene unc-22
(Moerman and Baillie 1979; Benian et al. 1993). We chose
this sgRNA both because unc-22 loss of function causes a dis-
tinctive recessive paralyzed twitching phenotype that is easy
to score and because this sgRNA works moderately well
compared to other sgRNAs (Table S1). Thus, F1 and F2
unc-22 twitchers should arise from animals exposed to the
greatest levels of Cas9 activity and should therefore also
have active Cas9 loaded with the co-injected sgRNAs.
To test the Co-CRISPR strategy, we co-injected the unc-22
sgRNA with two previously validated sgRNAs targeting
avr-14 and avr-15 (Figure 2A), two genes whose wild-type
activities redundantly confer sensitivity to the potent nemati-
cide ivermectin (Dent et al. 2000). The rol-6 marker was also
included in these injections to facilitate the identiﬁcation of
twitchers that arise in the F2 among the progeny of F1 roller
animals. We then measured, among 55 F1 rollers, the fre-
quency of ivermectin-resistant strains (20%, n = 11) and
twitcher strains (11%, n = 6) (Figure 2A). Strikingly, selecting
Figure 1 Efﬁcient CRISPR-Cas9-mediated gene disruption in transgenic animals. (A) Schematic of screen for CRISPR-Cas9 genome editing events. The
dominant transformation marker rol-6 was co-injected with Cas9, pie-1a sgRNA, and donor plasmids. F1 rollers were screened for NHEJ-mediated indels
by DNA sequencing. Among 93 F1 rollers, 22 indels were obtained. (B) Sequences of the wild-type pie-1 target site (top) and CRISPR-Cas9-mediated
indels among F1 animals: (i) pie-1 homozygotes carrying the same indel on both alleles; (ii) pie-1 homozygotes carrying a different indel on each allele;
and (iii) pie-1 heterozygotes. Lowercase letters indicate insertions, and dashes indicate deletions. The PAM is marked in red, and target sequences are
marked in blue. The number of deleted (2) or inserted (+) bases is indicated to the right of each indel. The numbers in parentheses in (iii) represent the
number of animals with the indels shown.
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for the twitching phenotype dramatically enriched for ani-
mals exhibiting ivermectin resistance. For example, among
8 F1 animals that were either twitching themselves or pro-
duced twitcher progeny, 7 (88%) also produced progeny
resistant to ivermectin (Figure 2, A and C). We conﬁrmed
Co-CRISPR activity by sequencing the lesions in several of
these strains (Figure 2B).
Similar results were obtained in several additional Co-
CRISPR experiments (Figure 2C and data not shown). For
example, we used this approach to test two uncharacterized
sgRNAs targeting the 39 end of pie-1 (Figure 2C and Figure
S1B). Among 11 twitcher lines identiﬁed in the F1 or F2, we
identiﬁed three indels by PCR and PAGE for one of the two
sgRNAs (Figure S1B) and a single indel for the other sgRNA
(Figure S1C). Sequence analysis conﬁrmed these indels,
which included a 6-nt deletion, a 24-nt insertion, and an
11-nt deletion for one sgRNA and a 16-nt insertion for the
other. However, the PAGE detection method clearly under-
estimated the frequency of indels. Sequence analysis identi-
ﬁed three heterozygous deletion mutations of 42, 43, and
603 nt that deleted primer binding sites and were thus too
large to be detected by our PCR and PAGE analysis (Figure
S1B). These unusually large deletions may reﬂect simulta-
neous cutting induced by the two adjacent sgRNAs whose
targets are separated by 61 bp in this experiment (Figure
S1B). In conclusion, these ﬁndings suggest that PAGE anal-
ysis of 10–20 Co-CRISPR lines should be sufﬁcient to de-
termine if an uncharacterized sgRNA is active. It should be
Figure 2 “unc-22” Co-CRISPR as a marker to indicate actively expressed Cas9. (A) Schematic of Co-CRISPR strategy to identify functional sgRNAs
targeting avr genes. sgRNAs targeting avr-14 and avr-15 were co-injected with a functional unc-22 sgRNA, the Cas9 expression vector, and the rol-6
transformation marker. F1 rollers or twitchers were transferred to individual plates. The plates were allowed to starve, and then they were copied to
plates containing 2 ng/ml ivermectin to identify CRISPR-Cas9-induced avr-14; avr-15 double mutants. (B) Indel sequences in avr-14; unc-22; avr-15 triple
mutants. avr-15 isolate 15 carried different indels on each allele. Sequences labeled with a question mark could not be precisely determined. (C)
Comparison of twitcher-based indel frequency and roller-based indel frequency.
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noted that since many F1 rollers analyzed were heterozy-
gous for unc-22 lesions, it was usually possible to ﬁnd non-
Unc segregants with an indel in the co-targeted gene using
the unc-22 Co-CRISPR assay. However, if unc-22 is inconve-
nient for a particular experiment, our ﬁndings suggest that
alternative Co-CRISPR sgRNAs targeting, for example, genes
that when mutated confer resistance to ivermectin or beno-
myl or other genes with visible mutant phenotypes may be
substituted (Table S1).
The observation that using nearby sgRNAs can induce
deletions that remove the intervening sequence is consistent
with previous ﬁndings in which large deletions were pro-
duced in this way (Horii et al. 2013; Ran et al. 2013; Ren
et al. 2013; Wang et al. 2013; Zhou et al. 2014). Thus the
Co-CRISPR strategy should facilitate the identiﬁcation of
deletions that remove the interval between two sgRNAs.
However, further experimentation will be required to deter-
mine how large an interval can readily be eliminated. For
the purpose of validating sgRNAs, our ﬁndings suggest that
large deletions produced by testing multiple nearby sgRNAs
simultaneously may confound the analysis of which sgRNAs
are active. On the other hand, pooling sgRNAs targeting
a number of different genes that are distant from one an-
other in the genome should, in principle, allow several
sgRNAs to be validated in a single Co-CRISPR micro-injection
experiment.
Identiﬁcation of HR events without
a coselectable marker
We next sought to use CRISPR-induced double-strand
breaks to drive HR. Several types of editing are possible,
ranging from changing a single amino acid to inserting
a protein tag such as GFP, or even deleting the entire target
gene. In designing donor molecules to introduce point
mutations or epitope fusions, we found it necessary to alter
the sgRNA target sequence in the donor by mutating the
protospacer adjacent motif (PAM) site or by introducing
mismatches within the seed region (Jinek et al. 2012; Cong
et al. 2013; Jiang et al. 2013; Sternberg et al. 2014). In our
experience, failure to take this step frequently results in HR
events containing CRISPR-Cas9-induced indels or a very low
frequency of HR events, sometimes 0% (data not shown).
Previous studies successfully used single-strand oligonu-
cleotide donor molecules (Zhao et al. 2014) or double-
strand plasmid donor molecules (Dickinson et al. 2013) to
induce HR events in C. elegans. However these studies relied
on screening for a selectable phenotype introduced by the
HR event. Given the high frequencies of NHEJ events
detected in the studies above, we wondered if CRISPR-
Cas9-mediated HR events could be recovered directly with-
out the need for selection.
To test this idea, we decided to use CRISPR-Cas9-
mediated HR to introduce the gfp coding sequence immedi-
ately downstream of the start codon in the endogenous pie-1
locus (Figure 3A). The donor plasmid in this experiment
contained NheI restriction sites ﬂanking the gfp coding se-
quence, 1-kb homology arms, and a silent mutation that
disrupts the PAM sequence at the sgRNA target site (Figure
3A). We generated three different donor constructs: gfp::pie-
1(WT), gfp::pie-1(K68A), and gfp::pie-1(K68R). Each donor
molecule was co-injected with vectors to express the sgRNA,
Cas9, and rol-6 marker. We then directly examined the
resulting F1 rolling animals for GFP::PIE-1 expression in
the germline and embryos using epiﬂuorescence microscopy
(Figure 3B, see Materials and Methods). Using this approach,
we obtained 9 independent gfp::pie-1(K68A) lines from 92
F1 rollers, 1 gfp::pie-1(K68R) line from 69 F1 rollers, and 1
gfp::pie-1(WT) line from 72 F1 rollers. Subsequent analyses
revealed that each of these F1 animals was heterozygous for
gfp::pie-1, and each strain incorporated both the gfp coding
sequence and the PAM site mutation, as well as the linked
K68A and K68R missense mutations. For unknown reasons,
we found that one of the nine gfp::pie-1(K68A) lines could
not be maintained.
The high rates of HR observed in the above study
suggested that it should also be possible to recover HR
events by screening DNA isolated from F1 rollers using PCR.
To test this idea, we designed donor molecules to insert the
pie-1 lysine 68 lesions without tag sequences (Figure S2A)
or to insert sequences encoding the FLAG epitope immedi-
ately before the stop codon of the pie-1 gene (Figure 3F). For
these HR experiments, we used 300 bp (no tag) and 800 bp
(ﬂag tag) ﬂanking homology arms along with previously
tested sgRNAs (Figure 3F, Figure S1B, and Figure S2A).
We then used PCR to amplify the genomic DNA sequence
from F1 rollers and restriction analysis to identify F1 heter-
ozygotes carrying the desired insertion (Figure 3G, Figure
S2, B and C). These studies identiﬁed two K68A HR events
among 93 F1 rollers (60 injected worms) and three ﬂag HR
events among 84 F1 rollers (40 injected worms) (data not
shown). A similar PCR-detection strategy was used to intro-
ducemcherry into the gene vet-2. In this experiment, mCherry
expression was not visible in adult F1 rollers, but was easily
detected among the F2 embryos produced by PCR-positive
animals (Figure 3E). Taken together these ﬁndings show that
CRISPR-Cas9-mediated HR occurs at a remarkably high fre-
quency in C. elegans.
We compared the expression and localization of GFP::PIE-1
protein in our newly generated gfp::pie-1 knock-in strains
to strains in which gfp::pie-1 was inserted at a heterologous
site in the genome by MosSCI (Frokjaer-Jensen et al. 2008;
Shirayama et al. 2012). The knock-in strains showed the
expected localization of PIE-1 in two- to four-cell embryos
(Figure 3C). Strikingly, immunoblot analysis using the PIE-1
monoclonal antibody (P4G5) revealed that GFP::PIE-1 pro-
tein was expressed at a much higher level in the CRISPR-
Cas9-induced knock-in strains, similar to the expression
level of endogenous PIE-1 protein (Figure 3D). These results
are consistent with a previous study (Dickinson et al. 2013)
and indicate, perhaps not surprisingly, that insertion of GFP
into the endogenous locus can achieve near optimal expres-
sion levels of the tagged protein.
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Figure 3 HR-mediated knock-in to generate fusion genes at endogenous loci. (A) Schematic of the Cas9/sgRNA target site and the donor plasmid for
gfp::pie-1 knock-ins. The donor plasmid contains the gfp coding sequence inserted immediately after the start codon of pie-1, 1 kb of homology
ﬂanking the CRISPR-Cas9 cleavage site, and a silent mutation in the PAM site. (B) Strategy to screen for gfp knock-in lines. We placed three F1 rollers at
a time on a 2% agar pad and screened for GFP expression using epiﬂuorescence microscopy. GFP-expressing worms were individually recovered and
allowed to make F2 progeny for 1 day before being lysed for PCR and DNA sequence analysis. We conﬁrmed Mendelian inheritance of gfp knock-in
alleles among F2 progeny. (C) GFP::PIE-1 expression in the germline of two- to four-cell embryos of gfp::pie-1 knock-in strains. (D) Immunoblot analysis
showing PIE-1 expression levels in wild-type animals, MosSCI-mediated gfp::pie-1 knock-in animals, and CRISPR-Cas9-mediated gfp knock-in animals. A
MosSCI strain of gfp::pie-1; pie-1(zu154) was obtained by crossing gfp::pie-1 (LGII) with the pie-1(zu154) (LGIII) null mutant. (E) mCherry expression in
late embryos of the mCherry::vet-2 knock-in strain. (F) Schematic of Cas9/sgRNA target sequence, PAM site, and donor plasmid for pie-1::ﬂag knock-in.
The PAM is located in the last exon of pie-1. The donor plasmid includes ﬂag coding sequence immediately before the pie-1 stop codon and 800-bp
homology arms ﬂanking the target site. (G) PCR and restriction analysis of an HR event. PCR products were generated using the primers indicated in F,
and the products were digested with NheI. The pie-1::ﬂag gene conversion introduces an NheI RFLP that is observed in F1 heterozygous and F2
homozygous pie-1::ﬂag animals.
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Co-CRISPR for identifying HR events
Most of the HR work described above was performed before
we realized the utility of Co-CRISPR markers for validating
sgRNAs. To determine if the Co-CRISPR strategy could
facilitate recovery of HR events, we co-injected unc-22 sgRNAs
along with CRISPR HR injection mixes targeting vet-2, pie-1,
and smo-1 genes (Figure S3). The ﬁndings from these studies
suggest that using a Co-CRISPR marker can increase the fre-
quency of HR events in the range of approximately two- to
fourfold over those observed by ﬁrst selecting F1 roller animals
(Table 1). Interestingly, however, these studies required a mod-
iﬁcation to the Co-CRISPR screening strategy. For testing
sgRNAs using Co-CRISPR, we found that F1 and F2 twitchers
were equally likely to exhibit co-induction of indels with the
second sgRNA. However, our data suggest that HR events were
not enriched and might be depleted among nonrolling, F1
twitcher animals. One possible explanation for this surprising
ﬁnding is that Cas9–sgRNA complexes may assemble in the
germline cytoplasm and then segregate into maturing oocytes
independently of the co-injected DNA (including both the
roller DNA and of course the donor DNA plasmids). Zygotes
inheriting programmed Cas9 could undergo NHEJ, but HR-
directed repair would not be possible without the donor vector.
Consistent with this reasoning, we found that in most cases HR
events were enriched only among F1 animals that were both
rolling, and thus had inherited the injected DNA, and also
segregated twitching progeny, indicating that Cas9 was active
(Table 1). For example among 145 F1 rollers, we found seven
animals heterozygous for a 39 insertion of gfp into the pie-1
locus. Among the F1 twitchers that were nonrolling, zero were
GFP positive, while among the 4 F1 rollers that segregated
twitching progeny, 2 (50%) were GFP positive. One convenient
aspect of searching for HR events among F1 rollers heterozy-
gous for unc-22 twitchers was that the unlinked twitcher
phenotype could easily be segregated away in subsequent
generations. These ﬁndings suggest that Co-CRISPR screen-
ing can enhance the detection of HR events. Indeed, we al-
ways found at least one HR event among the F1 rollers with
twitcher progeny (3/29, 2/4, and 1/12). However, in most
cases additional HR events were also recovered by scoring all
the F1 rollers (Table 1).
A selection/counterselection strategy for recovering
HR events
The above ﬁndings demonstrate that selections are not
necessary for identifying and recovering HR events using the
CRISPR-Cas9 system. However, for some experiments a domi-
nant selection could save considerable time and expense,
especially where insertion of heterologous DNA is likely to be
tolerated, for example, when generating a null allele of a gene
or when one wishes to precisely delete noncoding genes or
regulatory elements. The inserted marker also has the potential
beneﬁt of providing a selection for maintaining strains that
may not be homozygous viable. Previous studies have described
several selection strategies, including unc-119, NeomycinR,
PuromycinR, and HygromycinR (Frokjaer-Jensen et al. 2008;
Giordano-Santini et al. 2010; Semple et al. 2010; Frokjaer-Jensen
et al. 2012; Radman et al. 2013). To test a selection/
counterselection scheme for CRISPR-induced HR, we decided
to employ the unc-119(+) marker as well as a new worm
antibiotic-resistance marker expressing the bacterial BSD
gene as selectable markers and the avr-15 gene as a counter-
selectable marker. We have previously shown that introduc-
ing an avr-15(+) plasmid into extrachromosomal arrays and
balancer chromosomes can be used to facilitate their coun-
terselection by growth on ivermectin (Duchaine et al. 2006;
Shirayama et al. 2012). This counterselection can be thus
used to remove Cbr-unc-119(+) or BSD(+) extrachromosomal
transgenes, thereby facilitating the recovery of animals bearing
an HR-induced insertion of the selectable marker. This counter-
selection approach requires a starting strain resistant to iver-
mectin, which is conferred by lesions in both the avr-14 and
avr-15 genes. Ivermectin-resistant double-mutant strains are es-
sentially wild type in appearance, and Cbr-unc-119 ivermectin-
resistant strains are available, or as noted above, new strains
can readily be rendered ivermectin resistant by simply
co-injecting sgRNAs targeting avr-14 and avr-15 (Figure 2).
To test this selection/counterselection strategy we ﬁrst
designed a donor plasmid containing the BSD gene ﬂanked
with 1-kb pie-1 homology arms (Figure 4A). We injected 58
ivermectin-resistant animals with a mix containing this donor
plasmid along with a validated pie-1 sgRNA vector, the Peft-3::
Cas9 vector, the rol-6 vector, and the avr-15(+) vector. Gravid
F1 rollers were then placed 11 per plate directly onto plates
containing both blasticidin and ivermectin (Figure 4B; see
Materials and Methods). After 3–4 days we found that 3 of
14 plates produced blasticidin-resistant, fertile animals (Figure
4B). In a second experiment, we injected the same injection
mixture into 40 animals and obtained 103 F1 rollers, from
which we identiﬁed four blasticidin-resistant strains. In each
case, the desired HR events were conﬁrmed both by phenotype
and DNA sequence analysis (data not shown).




















ﬂag::vet-2/vet-2 40 29/65 0 62 2/62 (3%) 4/65 (6%) 3/29 (10%)
pie-1::gfp/pie-1 40 4/145 0 7 0/7 (0%) 7/145 (5%) 2/4 (50%)
smo-1::ﬂag/smo-1 40 12/55 10 22 1/22 (5%) 1/55 (2%) 1/12 (8%)
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We also tested Cbr-unc-119(+) as a selectable marker in
this selection/counterselection assay. For this experiment we
sought to enlarge an oma-1 deletion (tm1396), replacing
the oma-1 promoter, coding region, and 39UTR with the
cb-unc-119(+) gene ﬂanked by loxP sites (Dickinson et al.
2013) (Figure S4). We injected 15 ivermectin-resistant Cbr-
unc-119; oma-1(tm1396) animals with a mix containing
oma-1 sgRNA, Cbr-unc-119(+) oma-1 gene replacement do-
nor vector, a heat-shock Cas9 vector, the rol-6 vector, and the
avr-15(+) vector. Injected animals were allowed to recover
for 2 hr after injection and were then heat shocked at 34 for
1.5 hr (Waaijers et al. 2013). Gravid non-Unc F1 rollers
were collected 15 per plate on six plates, and each popula-
tion was subjected to ivermectin counterselection. After 4
days, one of the six plates produced healthy ivermectin re-
sistant non-Unc-119 nonrolling animals. Insertion of the
Cbr-unc-119 vector and deletion of the oma-1 sequences
was conﬁrmed by PCR (data not shown).
Optimizing sgRNA and donor molecule selection
There is much work still to do to optimize CRISPR
methodology for C. elegans. For example, it remains unclear
at this point why upward of half of the sgRNAs tested fail to
induce events. The sgRNAs that we have tested and the
activities observed are summarized in Table S1, and all of
the active sgRNA vectors will be made available (through
Addgene). Another area requiring more study is how best to
optimize HR donors. All of the HR donor molecules used in
the experiments described here were circular plasmids with
at least 300-bp homology arms (Figure S2A). For GFP in-
sertion we used either 800-bp or 1-kb homology arms and
observed roughly equal frequencies of HR in both cases
(Figure 3A and Figure S3B). Future studies should explore
shorter homology arms and other types of donor molecules
including linear dsDNA donor molecules produced, for ex-
ample, by PCR, as well as chemically synthesized ssDNA. It
will also be important to explore the optimal distance be-
tween the cut site and the homology arm. Increasing this
distance requires longer gene-conversion tracts and in other
organisms is correlated with reduced frequency of the de-
sired homologous event (Paques and Haber 1999). Our ﬁnd-
ings suggest that gene-conversion tracts of 250 bp are
common in C. elegans. Optimizing HR conditions for each
type of donor molecule will likely require extensive experi-
mentation to generate statistically signiﬁcant ﬁndings on
relative efﬁciencies. Although there is still much work to
do, the efﬁciencies reported here are already remarkably
high. For example, indels were frequently identiﬁed in
.10% of F1 rollers, and the ratio of HR events to the total
number of CRISPR-Cas9-induced-repair events was consis-
tently 10% in experiments where both HR and indels were
monitored.
Our ﬁndings provide a versatile framework for using
CRISPR-Cas9 genome editing in C. elegans, and the Co-CRISPR
strategy we employ is likely to be of value for CRISPR-Cas9
studies in other organisms. The tools described here, how-
ever, are likely to be just the beginning of what will be
possible in the near future. For example, the use of catalyt-
ically inactive Cas9 fusion proteins to tether regulators to
DNA targets has not been described yet in C. elegans, but
it is already ﬁnding many exciting applications in other sys-
tems (Cheng et al. 2013; Larson et al. 2013; Mali et al.
2013a; Qi et al. 2013; Kearns et al. 2014). CRISPR-Cas9
technology should also dramatically facilitate the use of
other nematode models, including species distantly related
to Caenorhaditis elegans and perhaps parasitic nematodes.
The ability to efﬁciently engineer genomes will only enhance
Figure 4 A blasticidin-resistance marker to select pie-1 knockout
mutants. (A) Schematic of the Cas9/sgRNA target sequence and an HR
donor plasmid in which a heterologous blasticidin-resistance (BSD) gene
replaces a region of pie-1 and is ﬂanked by 1-kb homology arms. The BSD
gene is under the control of the rpl-28 promoter (568 bp) and 39-UTR
(568 bp). (B) Schematic of the blasticidin selection strategy to precisely
delete the pie-1 gene. pie-1a sgRNA was co-injected with the Cas9 ex-
pression vector, the rol-6 transformation marker, the pie-1Δ::BSD donor
construct, and the pCCM416::Pmyo-2::avr-15(+) counterselection vector.
The indicated number of F1 rollers was transferred to the plates contain-
ing 2 ng/ml ivermectin to select against the extrachromosomal array and
100 mg/ml blasticidin to identify BSD knock-in lines. We identiﬁed two
plates with resistant, fertile adults among 14 plates, 3–4 days after trans-
ferring animals.
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the utility of model organisms where gene variants can now
be generated and analyzed rapidly and cost effectively, fa-
cilitating the production of new animals models for human
disease-associated alleles. Moreover, CRISPR-Cas9-engineered
strains with special alleles of important genes can be used as
starting strains in forward genetic screens, including sup-
pressor and enhancer screens, which are extremely powerful
in C. elegans. It is now easier than ever for researchers to use
C. elegans to explore the function of conserved genes of
interest. Indeed, the CRISPR-Cas9 technology lowers the
barrier to move from one system to another, effectively
making all organisms one, when exploring conserved cel-
lular mechanisms.
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GCG CTC AAG ATC ACT CCA TTG GCT CAG ATT GAC GAG GCG CCG GCA ACT AAA AGA CAT AGC TCG GCG
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TTC CAT ATT TTG TTT TGT ATA TTT ATC CAC TCA CCC CCT CTC TTT GTC CTG TGA ATG AAC TTG TGC CAA
AAG GTA TAA AAC AAA ACA TAT AAA TAG GTG AGT GGG GGA GAG AAA CAG GAC ACT TAC TTG AAC ACG GTT
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ACG GGC GGT GCG TTT GAA GTG TTC CCC GAT GGA TTC TTC TCT CAG CCA CCA CCA ACT ATT ATT TCC TAA
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TGC CCG CCA CGC AAA CTT CAC AAG GGG CTA CCT AAG AAG AGA GTC GGT GGT GGT TGA TAA TAA AGG ATT
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Figure S1. Detecting small indels on 15% polyacrylamide gels.  (A) The 
indicated primers (arrows) were used to amplify sequences immedi-
ately surrounding the CRISPR-Cas9 target site (red). The indels in this 
experiment were from an HR experiment, so an initial PCR was 
performed using primers outside of the homology arms of the donor 
template (Figure S2A). The initial PCR was used as a template to ampli-
fy the target site using the indicated primers. PCR products from F1 
heterozygotes (left) and F2 homozygotes (right) were separated on a 
non-denaturing 15% polyacrylamide gel and stained with ethidium 
bromide. The asterisk indicates the PCR product ampliﬁed from residu-
al donor plasmids in the single worm lysate (B) and (C) Test of two 
uncharacterized pie-1 sgRNAs using the Co-CRISPR strategy and PAGE 
analysis. The pie-1 sgRNA vectors were combined and co-injected with 
the unc-22 sgRNA, Cas9, and rol-6 plasmids. The pie-1 sgRNA target 
sites (shown in red and blue) are separated by 61 bp. As this experi-
ment did not include an HR donor, only a single round of PCR was 
performed with the indicated primers (arrows). We lysed 11 F1 animals 
with the twitching phenotype (#3, #8, and #9-11) or that produced 
twitching progeny (#1-2 and #4-7). WT, wild type N2 genomic DNA was 
used as a template. Asterisks indicate lanes in which small indels were 
detected. The ﬁlled triangles indicate lanes in which the primer pair 
could not detect the indels.












N2 G T C C A A A G C G T  
P K R


































Figure S2. Site-speciﬁc mutagenesis of pie-1 by HR. (A) Schematic of the 
Cas9/sgRNA target sites in pie-1 locus and donor plasmids. The K68A donor 
plasmid contains ~300 bp of homology ﬂanking the 52 bp target region 
between the K68 codon and PAM site and introduces a PmlI restriction site 
(red box). The PAM site of each donor was disrupted by silent mutations so 
that it will not be targeted by CRISPR-Cas9. The blue bar indicates the PAM 
site, and the red bar indicates the position of K68. (B) PCR and restriction 
enzyme analysis of wild type control worms and F1 rollers from K68A 
CRISPR-Cas9-mediated HR experiments. PCR primers outside of the donor 
homology arms (P1F and P1R for K68A) are indicated in (A). Restriction 
analysis following PCR shows the RFLP in pie-1(K68A)/+. The wild type 
product is indicated by the ﬁlled triangle. (C) DNA sequence analyses to 
conﬁrm the desired point mutations. Note that the PCR products for 
sequencing were ampliﬁed using the primers outside of donor plasmid, as 
indicated in (A).
3 SI H. Kim et al.
ATAGTCCTCTACCTACACTCTAATCCGAAAACAAACACCCATCAATCCCTTTTCCACTGAGATACTCGGTTT
ATCAGGAGATGGATGTGAGATTAGGCTTTTGTTTGTGGGTAGTTAGGGAAAAGGTGACTCTATGAGCCAAA
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Figure S3. HR donor plasmids used in Co-CRISPR experiments. (A) Schematic of the 
ﬂag::vet-2 donor plasmid. The ﬂag coding sequence was inserted immediately after the 
vet-2 start codon and ﬂanked by ~1200 bp homology arms. (B) Schematic of the pie-1::gfp 
donor plasmid. (C) Schematic of the smo-1::ﬂag donor plasmid. The donor plasmid includes 
ﬂag coding sequence immediately before the smo-1 stop codon and asymmetrical homolo-
gy arms (~800 bp and ~500 bp) ﬂanking the target site, and the Cas9/sgRNA target 
sequence is located in the 3’UTR of smo-1. The PAM sites mutated in each donor indicate 
the locations of the Cas9/sgRNA target sites. 
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tm1396 (1517 bp deletion)
Figure S4. Selection/counterselection experiment to delete the entire  oma-1(tm1396) locus. 
Schematic of the Cas9/sgRNA target site and the donor plasmid containing Cbr-unc-119(+) ﬂanked 
by loxP sites and 1 kb homology arms. The indicated primers OM-F and OM-R were used for PCR 
analysis.
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Table S1. Summary of sgRNAs sequences and their efficiency 
 
 
Name Sequence S/AS % efficiency 
avr-14 no.1 GAATATTGAAAGACTATGAT(TGG) S 10 
avr-14 no.2 GATTGGAGAGTTAGACCACG(TGG) S 20 
avr-15 no.9 GCAGAAAATGAATGTCATAC(AGG) AS HIGH 
avr-15 no.10 GTTTGCAATATAAGTCACCC(AGG) AS HIGH 
unc-22 no.2 GAACCCGTTGCCGAATACAC(AGG) S 5 
unc-22 no.9 GCCTTTGCTTCGATTTTCTT(TGG) AS 0 
unc-4 no.1 GTTATCGTCATCCGGTGACG(TGG) AS 10 
rde-3 no.3 GAATTTGAGCTTGAACGAGC(TGG) AS LOW 
rde-3 no.4 GTCGATACTTCAAAATTAAT(TGG) AS LOW 
lon-2 no.1 GGGAAACTATACCCTCACTG(TGG) S 30 
dpy-11 no.2 GCAAGGATCTTCAAAAAGCA(CGG) S 
0.4 
dpy-11 no.4 GATGCTTGTAGTCTGGAACT(GGG) AS 
unc-32 no.1 GATAGGAAGCATCAGATTGA(AGG) AS 
0 
unc-32 no.2 GTTGCTGAACTGGGAGAGCT(CGG) S 
bli-2 no.1 GGATTTGCTGCTACTGAATC(CGG) AS 
0 
bli-2 no.2 GATGGACGGGATGGTAGAGA(TGG) S 
dpy-5 no.2 GTCGGATTCGGCGCTGCATG(CGG) S 
0 
dpy-5 no.3 GGTTTCCTGGAGCTCCGGCT(GGG) AS 
ben-1 no.3 GGATATCACTTCCCAGAACT(TGG) AS 
0 
ben-1 no.5 GGGAGAAAGTGATTTGCAGT(TGG) S 
pie-1 a GGCTCAGATTGACGAGGCGC(CGG) S 24 
pie-1 b GCTGAGAGAAGAATCCATCG(GGG) AS 15 
pie-1 c GGACAAAGAGAGGGGGTGAG(TGG) AS 7.5 
pie-1 d GTTGAGTGCAGCCATTTGCT(CGG) AS 5 
smo-1 a GCCGATGATGCAGCTCAAGC(AGG) S LOW 
smo-1 b GTGCACTTCCGTGTAAAGTA(TGG) S HIGH 
smo-1 c GTCTACCAAGAGCAGCTGGG(CGG) S HIGH 
smo-1 d GTATCTCAGTGGAAAAGGGA(TGG) S HIGH 
vet-2 GTTGGATCATAGGATACCGG(TGG) AS 38 
C35E7.6 GGGCACCATACCGAGTGATG(GGG) AS 100 








6 SI H. Kim et al.






avr-14 sgRNA_F GATTGGAGAGTTAGACCACGGTTTTAGAGCTAGAAATAGC 
avr-15 sgRNA_F GTTTGCAATATAAGTCACCCGTTTTAGAGCTAGAAATAGC 
unc-22 sgRNA_F GAACCCGTTGCCGAATACACGTTTTAGAGCTAGAAATAGC 
pie-1 a sgRNA_F GGCTCAGATTGACGAGGCGCGTTTTAGAGCTAGAAATAGC 
pie-1 b sgRNA_F GCTGAGAGAAGAATCCATCGGTTTTAGAGCTAGAAATAGC 
pie-1 c sgRNA_F GGACAAAGAGAGGGGGTGAGGTTTTAGAGCTAGAAATAGC 
smo-1 sgRNA_F GTATCTCAGTGGAAAAGGGAGTTTTAGAGCTAGAAATAGC 
vet-2 sgRNA_F GTTGGATCATAGGATACCGGGTTTTAGAGCTAGAAATAGC 
oma-1 sgRNA F GATCCAATGATGTCATGTAAGTTTTAGAGCTAGAAATAGC 
sgRNA_R (N)19CAAACATTTAGATTTGCAATTC 
avr-14 sgRNA_R CGTGGTCTAACTCTCCAATCAAACATTTAGATTTGCAATTC 
avr-15 sgRNA_R GGGTGACTTATATTGCAAACAAACATTTAGATTTGCAATTC 
unc-22 sgRNA_R GTGTATTCGGCAACGGGTTCAAACATTTAGATTTGCAATTC 
pie-1 a sgRNA_R GCGCCTCGTCAATCTGAGCCAAACATTTAGATTTGCAATTC 
pie-1 b sgRNA_R CGATGGATTCTTCTCTCAGCAAACATTTAGATTTGCAATTC 
pie-1 c sgRNA_R CTCACCCCCTCTCTTTGTCCAAACATTTAGATTTGCAATTC 
smo-1 sgRNA_R TCCCTTTTCCACTGAGATACAAACATTTAGATTTGCAATTC 
vet-2 sgRNA_R CCGGTATCCTATGATCCAACAAACATTTAGATTTGCAATTC 
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Table S3. Summary of primer sequences for repair template and PCR screening 
 
Name Sequence 
C_PIE-1 PF ATAGCCCGATTTTGGAGGTG 
C_PIE-1 PR CCTCGAATTTTGGCAATTTTTC 
C_PIE-1 301L ATGGATTTCTCGCCGTTTTTTC 





C_PIE-1 a MF GCTATGTCTTTTAGTTGCAGGCGCCTC 
C_PIE-1 a MR CAGATTGACGAGGCGCCTGCAACTAA 
SMO-1 PF CGATTTTTCGGCTCATTTCG 
SMO-1 PR CCTCGTCAAATCCGAAATCG 
SMO MF CACCCATCAATCCCTTTTC 
















MC. OUT F1 (vet-2) GCTCAAGAAAGCCAATGGAG 
MC. OUT R1 (vet-2) TTCTGAACCAGTCGATGCAG 
MC.IN F1 (vet-2) ATGGAGGGATCTGTCAATGG 
MC.IN R1 (vet-2) TGGCAGTCGAGACACTTCAG 
FL. IN F1 (vet-2) CACAAAACCGGCCAAAAA 




8 SI H. Kim et al.
